doi: 10.1158/2159-8290.CD-NB2021-0309.
Epub 2021 Feb 5.
Sotorasib Edges Closer to Approval
- PMID: 33547148
- DOI: 10.1158/2159-8290.CD-NB2021-0309
Item in Clipboard
Sotorasib Edges Closer to Approval
Cancer Discov.
2021 May.
Abstract
The KRASG12C inhibitor sotorasib continues to impress in non-small cell lung cancer: In the phase II CodeBreak 100 trial, the agent elicited responses in more than a third of patients and led to a median progression-free survival of almost 7 months. Based on these results, Amgen has filed for the drug's approval with the FDA and the European Medicines Agency.
©2021 American Association for Cancer Research.
Similar articles
-
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code.Lung Cancer (Auckl). 2023 Apr 19;14:27-30. doi: 10.2147/LCTT.S403461. eCollection 2023. Lung Cancer (Auckl). 2023. PMID: 37101895 Free PMC article.
-
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code.Lung Cancer (Auckl). 2023 Apr 20;14:31-39. doi: 10.2147/LCTT.S403614. eCollection 2023. Lung Cancer (Auckl). 2023. PMID: 37101896 Free PMC article.
-
Spotlight on Sotorasib (AMG 510) for KRAS G12C Positive Non-Small Cell Lung Cancer.Lung Cancer (Auckl). 2021 Oct 7;12:115-122. doi: 10.2147/LCTT.S334623. eCollection 2021. Lung Cancer (Auckl). 2021. PMID: 34675734 Free PMC article. Review.
-
KRAS Inhibitor Continues to Impress in NSCLC.Cancer Discov. 2020 Nov;10(11):1617. doi: 10.1158/2159-8290.CD-NB2020-089. Epub 2020 Oct 1. Cancer Discov. 2020. PMID: 33004338
-
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.Ann Oncol. 2021 Sep;32(9):1101-1110. doi: 10.1016/j.annonc.2021.06.001. Epub 2021 Jun 2. Ann Oncol. 2021. PMID: 34089836 Review.
Cited by
-
Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges.Front Cell Dev Biol. 2021 Sep 8;9:694363. doi: 10.3389/fcell.2021.694363. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34568317 Free PMC article. Review.
-
Targeting KRAS Regulation with PolyPurine Reverse Hoogsteen Oligonucleotides.Int J Mol Sci. 2022 Feb 14;23(4):2097. doi: 10.3390/ijms23042097. Int J Mol Sci. 2022. PMID: 35216221 Free PMC article.
-
Comprehensive tumor molecular profile analysis in clinical practice.BMC Med Genomics. 2021 Apr 14;14(1):105. doi: 10.1186/s12920-021-00952-9. BMC Med Genomics. 2021. PMID: 33853586 Free PMC article.
-
Indoloquinoline-Mediated Targeted Downregulation of KRAS through Selective Stabilization of the Mid-Promoter G-Quadruplex Structure.Genes (Basel). 2022 Aug 13;13(8):1440. doi: 10.3390/genes13081440. Genes (Basel). 2022. PMID: 36011352 Free PMC article.
-
Non-Oncogene Addiction of KRAS-Mutant Cancers to IL-1β via Versican and Mononuclear IKKβ.Cancers (Basel). 2023 Mar 20;15(6):1866. doi: 10.3390/cancers15061866. Cancers (Basel). 2023. PMID: 36980752 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
